Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ISM001 055

Drug Profile

ISM001 055

Alternative Names: INS018-055; INS018_055; ISM001-055

Latest Information Update: 29 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator InSilico Medicine
  • Class Antifibrotics; Skin disorder therapies; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Idiopathic pulmonary fibrosis
  • Research Skin disorders

Most Recent Events

  • 15 Dec 2023 Phase-II clinical trials in Idiopathic pulmonary fibrosis in USA (IV) (NCT05975983)
  • 04 Aug 2023 InSilico Medicine plans a phase II trial in Idiopathic pulmonary fibrosis in USA (PO, Capsule) in October 2023 (NCT05975983)
  • 19 Jun 2023 Phase-II clinical trials in Idiopathic pulmonary fibrosis in China (PO) (NCT05938920)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top